Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Sox10 Expression in Goldfish Retina and Optic Nerve Head in Controls and after the Application of Two Different Lesion Paradigms.
Parainfectious longitudinally extensive transverse myelitis associated with varicella-zoster virus.
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon.
Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.
Glial cells as drug targets: What does it take?
FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.
[Information processing speed and influential factors in multiple sclerosis].
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Flupirtine in pain management: pharmacological properties and clinical use.
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
Autoimmune myelopathies.
Geography in multiple sclerosis.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Relationship between neuromuscular and perceived fatigue and locomotor performance in patients with multiple sclerosis.
Demyelination induces transport of ribosome-containing vesicles from glia to axons: evidence from animal models and MS patient brains.
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
Teriflunomide in multiple sclerosis: Added benefit not proven
WT1 and interferon-β-vitamin D association in MS: a longitudinal study.
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
Pages
« first
‹ previous
…
42
43
44
45
46
47
48
49
50
…
next ›
last »